

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/271962 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 47/02 (2006.01)
A61K 38/37 (2006.01) A61K 47/18 (2017.01)
C07K 14/755 (2006.01) A61K 47/26 (2006.01)
A61K 9/19 (2006.01) A61P 7/04 (2006.01)

(21) International Application Number:

PCT/US2022/034747

(22) International Filing Date:

23 June 2022 (23.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/214,245	23 June 2021 (23.06.2021)	US
63/214,246	23 June 2021 (23.06.2021)	US
63/214,752	24 June 2021 (24.06.2021)	US
63/231,909	11 August 2021 (11.08.2021)	US

(71) Applicant: **BIOVERATIV THERAPEUTICS INC.**

[US/US]; 225 SECOND AVENUE, WALTHAM, Massachusetts 02451 (US).

(72) Inventors: **CARLAGE, Tyler**; c/o Sanofi, Patent Department,

450 Water Street, Cambridge, Massachusetts 02141 (US). **MAULDIN, Randall**; c/o Sanofi, Patent Department,

450 Water Street, Cambridge, Massachusetts 02141 (US). **TAZI, Loubna Mzaalak**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **MCCOY, Timothy R.**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **VELEMA, James H.** et al.; 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):


AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: FORMULATIONS OF FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF

FIG. 1



(57) Abstract: The present disclosure provides pharmaceutical compositions of a chimeric protein comprising a factor VIII (FVIII) polypeptide and a von Willebrand factor (VWF) polypeptide. Also disclosed are pharmaceutical kits and methods of using the disclosed pharmaceutical compositions to treat hemophilia A.

WO 2022/271962 A1

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*